Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Treatment of rats with PPARG agonist rosiglitazone increases...

Class:IdSummation:9907223
_displayNameTreatment of rats with PPARG agonist rosiglitazone increases...
_timestamp2024-04-05 00:03:59
created[InstanceEdit:9907225] Orlic-Milacic, Marija, 2024-04-05
textTreatment of rats with PPARG agonist rosiglitazone increases mRNA levels of MGLL and other lipolysis enzymes in subcutaneous and visceral white adipose tissue (Festuccia et al. 2006).
(summation)[BlackBoxEvent:9907224] rMgll gene expression is stimulated by rPparg:Rxra [Rattus norvegicus]
[Change default viewing format]
No pathways have been reviewed or authored by Treatment of rats with PPARG agonist rosiglitazone increases... (9907223)